More importantly, this shift in investor demographics could lead Bitcoin to new highs. Changing Demographics, Changing Price. Through the utilization of Coindance and its data, Stack Funds. Jul 11, · The Bitcoin price will go up as investor demographics change The report was found using data from Coindance that 50% of Bitcoin investors are millennials. Bitcoin investors demographics reached formidable Results in Studies. Using different individual Experience, you can find out, that the Preparation meets its requirements. This is amazingly, because nearly all further Producers permanent negative rated be. Myself could to .
Bitcoin investors demographicsSurvey Reveals Shifts In Bitcoin Ownership Demographics
In this sense, I look at Pfizer stock as a cautionary tale of what happens when investors get hooked on the promise of astronomical gains — even if the outfit has no product of which to speak — to the detriment of a company that just made one of the biggest product breakthroughs in history.
And I do. Wall Street, the financial news cycle and investors at large boast the collective attention span of three goldfish swimming in a bowl of espresso. Taking the long view is no longer fashionable. Investors and analysts often see such titans as stodgy and stuck. With Pfizer stock, slow and steady will always be slow and steady. All that mattered for them was practicing the right spin and dangling the carrot of easy investment pickings.
I am not sure that is a disease we can cure. Pfizer Stock and the Analyst Enigma Even the analysts in this case seem to confound expectations. In the first quarter of , when many companies were staving off a bloodbath, Pfizer beat analyst expectations.
Then it did it again in the second quarter. And it pulled off a three-peat in the third quarter. Despite this, 15 analysts call Pfizer stock a hold. At least the six who call it a buy tip the scale towards a consensus rating of overweight. As recently as Dec. Something positive, anyway. But since Dec. Year over year, shares have remained flat. The company did a great job promoting its vaccine candidate INO, all right. PFE even boasts a very attractive price-to-earnings ratio of So what do investors have against Pfizer stock?
I see this in part as symptomatic of our times, when investor perceptions can trump reality and investor sentiment can turn a frog into a prince and vice versa.
The company has been around forever. It just produced an astounding hybrid version of its F pickup and an all-electric Mustang Mach-E. Yet Ford gets no love from investors. Here we have a disgraced EV company that has admitted to faking footage of a fully operational prototype humming down the road. The car was actually an empty shell coasting down a hill. Nikola stock year over year?
The rest of the world is swept up in the irresistible tide of ESG investing. And yes, the goal is to not only support businesses that do good, but that do well financially. Yet somehow, the calculus is off. I hold Pfizer stock but find myself struggling to make a case for it. That is because investors will do what they will do and I believe a great many of them have already made up their minds to pass.
Even if the rest of the world rejoiced. After that, who knows? Tech stocks along with banks, aerospace, retail, and many other sectors have all had "their day in the sun" and now is the time for investors to pay closer attention to a "dream market" of alternative fuel companies, according to Jim Cramer. EV Play: Self-driving electric vehicles won't be possible without companies that manufacture the technology that powers the cars. EV cars will need access to charging stations.
Why The Interest: These "alternative energy-adjacent companies" boast expertise in unique technologies that used to be "too expensive" but have now become a lot cheaper to produce, Cramer said. The group is also benefiting from a potential catalyst from a Joe Biden administration that will be more supportive of alternative energy, Cramer said.
Finally, a chance that the lockdown and social distancing regimes truly are going to end, and in the near-term. There is a real chance that, by the end of a , John Q. Public may be getting back on his feet. A return to grass roots normalcy will be great — but we also have the prospect of an overall rising market. Risks relating to global trade tensions, political uncertainty, and the pandemic, will be going away. Sotera Health SHC Sotera Health occupies a unique niche in the healthcare industry, offering, through its subsidiaries, a range of safety-oriented support businesses for healthcare providers.
These services include sterilization procedures, lab testing, and advisory services — and their importance is immediately clear. Sotera boasts over 5, healthcare provider customers in more than 50 countries around the world.
While not a new company — two of its branches have been in business since the s and 40s — Sotera is new to the stock markets, having held its IPO just this past November. That facility is currently undrawn. This clinical research biopharma company focuses on major issues of reproductive system disease in both men and women.
Specifically, Myovant is working to develop treatments for uterine fibroids, endometriosis, and prostate cancer. The drug is in Phase 3 trial for the latter, and has had its NDA submitted for the former. Also in the pipeline, and related to reproductive health, is MVT, a new drug designed to enhance egg maturation and aid in vitro fertilization. In addition, Myovant has announced this month that Relugolix has been FDA approved — under the brand name Orgovyx — as a treatment for advanced prostate cancer.
Orgovyx is expected to enter the market in January Further, we see an attractive commercial setup for relugolix in the treatment of advanced prostate cancer as an oral LHRH alternative with a differentiated CV risk profile. In a year that has been difficult for most of us, MCB has managed to post steadily increasing revenues and solid earnings. In this environment, he sees Metropolitan Bank as the right choice. Having witnessed many cycles in NYC, the time to buy has been when the herd is running in the other direction.
Alexopoulos' is the only recent analyst review of this company, and it is decidedly positive. First thing's first, what are penny stocks? Penny stocks are well-known for their volatility aside from just their cheap price.
First, understand what you're buying and why you're buying it. Just saying you trade penny stocks isn't the goal. You're in the market to make money. So, identifying entry and exit targets are obviously important. What's more, is you should have a basic strategy in mind.
Are you looking at day trading penny stocks or do you have a longer-term idea in mind? Also, it's important to account for the swings in price and how fast they're happening.
Case in point, small-cap stocks are red hot right now. When finding penny stocks to buy, make sure you assess each trade independently and plan accordingly. Furthermore, day traders wouldn't normally jump into a stock that is barely fluctuating in price.
As a rule of thumb, the lower the price, the higher the volatility. That's simply for the fact that a small move in price equates to a larger percentage change. This week the company came out with news that it finished the purchase of roughly 44 acres in Montana.
This will be the site for its vaccine development and manufacturing facility. This adds to the growing footprint of the company as well. These two facilities will support the development and production of the company's vaccine candidates. Specifically, the TNX has been a center of attention as you could imagine. Many coronavirus vaccine stocks have garnered interest over the last few months. In this case, Tonix is aiming to report efficacy data from animal challenge studies of the vaccine candidate next quarter.
Unlike other biotech's Biolase is mainly focused on products used in oral health. The company's main products are dental laser systems that perform a wide range of procedures, including cosmetic and complex surgical applications. Last month the company launched Waterlase Endo Academy to foster education and best practices for integrating Waterlase technology in clinical settings.
Jaguar Health Inc. While we've reported on the company for weeks, the bigger move this week comes after Jaguar's latest update. The company signed an agreement for a non-dilutive royalty financing transaction. Lisa Conte, Jaguar's president and CEO, explained that, "The timing of this transaction aligns well with the progress of the recently initiated pivotal Phase 3 trial for CTD, for which patient enrollment is progressing.
There's a potential deal with the SPAC and an operational subsidiary of Jaguar to be established in Europe with an exclusive license to crofelemer and Mytesi for the indications of inflammatory diarrhea and HIV-related diarrhea.
Senseonics Holdings Inc. Senseonics was granted a patent titled, "Remotely-powered sensing system with multiple sensing devices.
Senseonics' implantable glucose monitoring systems are used by diabetes patients. This communicates with a smart transmitter worn over the sensor. Data are then sent every five minutes to a mobile app on the user's smartphone. Adding to the reasons to watch Senseonics, earlier this year the company entered a collaboration with Ascensia Diabetes Care, a global diabetes care company.
Heading into the beginning of , there are a few things traders are following. Please wait a minute before you try to comment again. Thanks for your comment. Please note that all comments are pending until approved by our moderators.
It may therefore take some time before it appears on our website. Follow this post. Unfollow this post. This comment has already been saved in your Saved Items. Author's response. Reply 0 0. Show more comments. Show more replies. Add Chart to Comment. Cancel Attach. Confirm Block. Confirm Block Cancel. Report this comment. I feel that this comment is: Spam Offensive. Comment flagged. Thank You! Your report has been sent to our moderators for review. But it was hardly a cause for celebration.
And a lot of them, at 9. Some Just 1. Despite Google getting plenty of pushback, Chrome is still the number one browser for Although that number in itself is significant. At first glance, that particular fact might not seem very interesting.
However, it reveals volumes when it comes to user security. After all, trading often requires multiple screens. From this data, clearly users are more comfortable transacting from the safety of their Mac or PC, than trading on-the-go with their smartphones. What do you make of these new findings? Let us know your thoughts in the comment section below!